SAT0546 The Regenerative Effect of Human Umbilical Cord Blood Mesenchymal Stem Cells in A Rabbit Model of Osteoarthritis
Authors: A.A.-R. Youssef, A.E.A. Afifi, H.A. Abd El Ghaffar, S.R. El-Basuny, O.M. Gharbia, A.K. El hawary, A.L. Mansour, A.E. Abd el hamid, A.A. Ezzat
Journal: Annals of the Rheumatic Diseases (2014)

<h3>Background</h3> Osteoarthritis (OA) is a degenerative disease with articular cartilage degradation accompanied by changes in subchondral and peri articular bone. The limited therapeutic choices for articular injury and disease increased the need for stem cells as a biological replacement of damaged cartilage [1]. Human Umbilical cord blood mesenchymal stem cells (HUCB-MSCs) are easily available and less immunogenic than other sources of stem cells, and there are no ethical concerns about using them. These cells are isolated from young donors. HUCB-MSCs appear to be ideal candidate for cartilage regeneration [2]. <h3>Objectives</h3> To study, the effect of (HUCB-MSCs) on repairing degenerated articular cartilage in experimentally induced osteoarthritis in New-Zealand white rabbit. <h3>Methods</h3> This study was conducted on forty two adult male New-Zealand white rabbits. All rabbits underwent surgically induced OA by cutting ACL in the left knees. At 12 weeks postoperative 2 rabbits were sacrificed, and the development of OA in knee joints were confirmed histopathologically. The other 40 rabbits were randomly assigned into 2 cell treated groups and 2 controls. Cells were characterized using cell surface markers by fluorescence-activated cell sorting (FACS) analyses [3]. We delivered a single dose of stem cells directly intra articular in the 2 cell treated groups. The 2 control groups were injected by suspension of media without cells. Histopathological study was performed twice at 12 weeks and 24 weeks post injection in all groups. <h3>Results</h3> Histopathologically, cell treated rabbits showed better cartilage quality and lower degree of degeneration at 12 weeks after injection. While at 24 weeks after injection all parameters of cell treated group including: Macroscopic grading [4], Histological grading [5] were significantly better than the control group P&lt;0.001 <h3>Conclusions</h3> The findings of the present study is the first to indicate that HUCB-MSCs are a promising cell source for cartilage tissue engineering and can reduce the development of OA lesions in a rabbit model. However, larger groups and longer periods of study may provide additional support for using this therapeutic approach as a new way of cartilage engineering in human. <h3>References</h3> Toghraie FS, Chenari N, Gholipour MA, et al. Treatment of osteoarthritis with infrapatellar fat pad derived mesenchymal stem cells in Rabbit. Knee; 2011: 18:71–75 Kim J., Hong B., Yoon S., et al. Application of human umbilical cord blood-derived mesenchymal stem cells in disease models. World J Stem Cells 2010 April 26; 2(2): 34-38 Wang HS, Hung SC, Peng ST, et al. Mesenchymal stem cells in the Wharton9s jelly of the human umbilical cord. Stem Cells; 2004; 22:1330–7. Yoshioka M, Coutts RD, Amiel D, Hacker SA. Characterization of a model of osteoarthritis in the rabbit knee. Osteoarthritis Cartilage 1996; 4:87-98 Mankin HJ, Dorfman H, Lippiello L, Zarins A: Biochemical and metabolic abnormalities in articular cartilage from osteo-arthritic human hips. II. Correlation of morphology with biochemical and metabolic data, J Bone Joint Surg Am 53(3):523–537, 1971. <h3>Acknowledgements</h3> We would like to express our deepest gratitude and thanks to all the staff members at department of rheumatology, and Medical Experimental Research Center, Mansoura University, Egypt. <h3>Disclosure of Interest</h3> A. Youssef Shareholder of: no conflict of interest, Grant/research support: no conflict of interest, Consultant for: no conflict of interest, Employee of: no conflict of interest, Paid instructor for: no conflict of interest, Speakers bureau: no conflict of interest, A. E. Afifi Shareholder of: no conflict of interest, Grant/research support: no conflict of interest, Consultant for: no conflict of interest, Employee of: no conflict of interest, Paid instructor for: no conflict of interest, Speakers bureau: no conflict of interest, H. Abd El Ghaffar Shareholder of: no conflict of interest, Grant/research support: no conflict of interest, Consultant for: no conflict of interest, Employee of: no conflict of interest, Paid instructor for: no conflict of interest, Speakers bureau: no conflict of interest, S. El-Basuny Shareholder of: no conflict of interest, Grant/research support: no conflict of interest, Consultant for: no conflict of interest, Employee of: no conflict of interest, Paid instructor for: no conflict of interest, Speakers bureau: no conflict of interest, O. Gharbia Shareholder of: no conflict of interest, Grant/research support: no conflict of interest, Consultant for: no conflict of interest, Employee of: no conflict of interest, Paid instructor for: no conflict of interest, Speakers bureau: no conflict of interest, A. El hawary Shareholder of: no conflict of interest, Grant/research support: no conflict of interest, Consultant for: no conflict of interest, Employee of: no conflict of interest, Paid instructor for: no conflict of interest, Speakers bureau: no conflict of interest, A. Mansour Shareholder of: no conflict of interest, Grant/research support: no conflict of interest, Consultant for: no conflict of interest, Employee of: no conflict of interest, Paid instructor for: no conflict of interest, Speakers bureau: no conflict of interest, A. Abd el hamid Shareholder of: no conflict of interest, Grant/research support: no conflict of interest, Consultant for: no conflict of interest, Employee of: no conflict of interest, Paid instructor for: no conflict of interest, Speakers bureau: no conflict of interest, A. Ezzat Shareholder of: no conflict of interest, Grant/research support: no conflict of interest, Consultant for: no conflict of interest, Employee of: no conflict of interest, Paid instructor for: no conflict of interest, Speakers bureau: no conflict of interest <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.2066